Ultimovacs ASA

Oslo Stock Exchange ULTI.OL

Ultimovacs ASA Free Cash Flow for the year ending December 31, 2023: USD -18.64 M

Ultimovacs ASA Free Cash Flow is USD -18.64 M for the year ending December 31, 2023, a -8.89% change year over year. Free cash flow is the amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.

Ultimovacs ASA Free Cash Flow for the year ending December 31, 2022 was USD -17.12 M, a -20.02% change year over year.
Ultimovacs ASA Free Cash Flow for the year ending December 31, 2021 was USD -14.26 M, a -7.81% change year over year.
Ultimovacs ASA Free Cash Flow for the year ending December 31, 2020 was USD -13.23 M, a -83.92% change year over year.
Ultimovacs ASA Free Cash Flow for the year ending December 31, 2019 was USD -7.19 M, a -22.22% change year over year.

Key data

Date	Free Cash Flow	Operating Cash Flow	Net Cash Used For Investing Activities	Net Cash Used Provided By Financing Activities

Oslo Stock Exchange: ULTI.OL

Ultimovacs ASA

CEO	Dr. Carlos de Sousa
IPO Date	June 3, 2019
Location	Norway
Headquarters	Ullernchausséen 64
Employees	17
Sector	Health Care
Industries Pharmaceuticals Biotechnology Vaccines

Description

Ultimovacs ASA, a pharmaceutical company, develops immunotherapies for cancers. Its lead product candidate is UV1, a peptide-based vaccine that induces T cell response against the universal cancer antigen telomerase. The company was incorporated in 2011 and is headquartered in Oslo, Norway.

Key trends

Past 5 years